Czech National Bank’s Zimmer Biomet ZBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.74M Buy
55,067
+1,093
+2% +$95.8K 0.03% 411
2026
Q1
$4.88M Buy
53,974
+1,717
+3% +$158K 0.03% 396
2025
Q4
$4.7M Buy
52,257
+1,944
+4% +$184K 0.03% 393
2025
Q3
$4.96M Buy
50,313
+1,952
+4% +$193K 0.03% 374
2025
Q2
$4.41M Buy
48,361
+2,637
+6% +$255K 0.03% 384
2025
Q1
$5.18M Buy
45,724
+2,560
+6% +$274K 0.05% 333
2024
Q4
$4.56M Buy
43,164
+1,678
+4% +$180K 0.04% 349
2024
Q3
$4.48M Buy
41,486
+2,282
+6% +$249K 0.05% 340
2024
Q2
$4.25M Buy
39,204
+2,434
+7% +$287K 0.05% 324
2024
Q1
$4.85M Buy
36,770
+169
+0.5% +$21.1K 0.06% 285
2023
Q4
$4.45M Buy
36,601
+79
+0.2% +$8.81K 0.06% 289
2023
Q3
$4.1M Buy
36,522
+11,831
+48% +$1.5M 0.07% 281
2023
Q2
$3.6M Sell
24,691
-31
-0.1% -$4.21K 0.08% 249
2023
Q1
$3.19M Buy
24,722
+155
+0.6% +$19.5K 0.08% 264
2022
Q4
$3.13M Buy
24,567
+183
+0.8% +$21.2K 0.08% 258
2022
Q3
$2.55M Buy
+24,384
New +$2.68M 0.07% 275

Other funds holding ZBH

Czech National Bank's ZBH Position: Q2 2026 in Review

Czech National Bank increased its Zimmer Biomet (ZBH) stake by 2% in Q2 2026, buying an estimated $95.8K and bringing the position to 55,067 shares worth $4.74M. The position accounts for 0.03% of the portfolio, ranked #411.

Czech National Bank first reported a position in ZBH in Q3 2022 and has held it in 16 quarters since. The position peaked at $5.18M in Q1 2025. 187 funds tracked by Wall St. Rank hold ZBH as of Q2 2026.

  • Czech National Bank held 55,067 shares of Zimmer Biomet worth $4.74M as of Q2 2026.
  • Czech National Bank bought 1,093 Zimmer Biomet shares in Q2 2026, an estimated $95.8K.
  • Zimmer Biomet made up 0.03% of Czech National Bank's portfolio in Q2 2026, its #411 holding.
  • Czech National Bank first reported a position in Zimmer Biomet in Q3 2022 and has held it in 16 quarters since.
  • Czech National Bank's Zimmer Biomet position peaked at $5.18M in Q1 2025.
  • 187 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2026.

Based on Czech National Bank's 13F filing for Q2 2026, filed 8 Jul 2026.